5 Key Takeaways

• 1

  Vorolanib, axitinib, and migaldendranib are investigational TKIs offering targeted therapy for neovascular age-related macular degeneration and diabetic macular edema.

• 2

  Current anti-VEGF therapies are effective but require frequent treatments, leading to patient undertreatment and increased burden on healthcare systems.

• 3

  Investigational TKIs function intracellularly to inhibit VEGFRs and other receptors, potentially providing new mechanisms of action for retinal disease treatment.

• 4

  Duravyu, a sustained-release intravitreal insert combining vorolanib, has shown promising results in clinical trials, reducing treatment burden significantly.

• 5

  In phase 2 trials, Duravyu demonstrated noninferior vision outcomes compared to aflibercept, with a high percentage of patients remaining injection-free.